Development of a Chlamydia trachomatis T cell Vaccine

This review mainly focuses on an immunoproteomic approach used in our laboratory to identify Chlamydia T cell antigens and how these T cell antigens can be developed into a future human Chlamydia vaccine

Karuna P. Karunakaran; Hong Yu; Leonard J. Foster; Robert C. Brunham


Scholarcy highlights

  • The immune correlates of protection for most of the currently used vaccines are based on long-lived humoral immunity
  • In jurisdictions where programs have been systematically introduced, C. trachomatis case rates have substantially fallen. This has been the experience in British Columbia, Canada where case rates were reduced by more than 50% between 1991 and 1997 following the introduction of a control program
  • The studies generated results that have endured as the fundamental paradigm of C. trachomatis vaccinology
  • The clinical data show that the immune correlates for protection against C. trachomatis infection are cell-mediated IFN╬│ responses; IL-10 responses correlate with susceptibility
  • We used the immunoproteomic approach to identify 13 Chlamydia peptides derived from 8 novel epitopes presented by MHC class II molecules from BM-dendritic cells infected with Chlamydia
  • The superior protection obtained in the protein combination group compared with individual protein group suggests that a successful Chlamydia vaccine will need to be composed of multiple proteins in order to provide broad coverage in an outbred population, to cross protect against multiple variants of C. trachomatis as well as to maximize immunogenicity
  • Since all the protection results described above were observed in C57BL/6 mouse, the strain in which the antigens were originally discovered by immunoproteomics, we tested the protection efficacy of multiple Chlamydia protein antigens and DDA/TDB in Balb/c mice that has a different MHC genetic background

Need more features? Save interactive summary cards to your Scholarcy Library.